PMC5221688_01
Direct comparison of transverse slices on the baseline FDG PET (upper row), work-up MAA SPECT (second row), 90Y PET derived dose map (third row), and 8 weeks follow-up FDG PET (bottom row) for each of the four lesions identified for SIRT. Lesions receiving an absorbed dose above the critical threshold can be seen to exhibit a complete response at the time of follow-up, whereas those receiving sub-threshold dosing exhibit stable disease
AOJNMB-5-66-g001.jpg
PMC5221688_01_AOJNMB-5-66-g001.jpg
F1
Follow-up FDG PET was acquired 8 weeks post-SIRT, demonstrating a complete metabolic response for lesions in segment 5 and 8, and stable disease (less than a 50% change in TLG) for lesions in segments 4a and 1 (Figure 1).
Direct comparison of transverse slices on the baseline FDG PET (upper row), work-up MAA SPECT (second row), 90Y PET derived dose map (third row), and 8 weeks follow-up FDG PET (bottom row) for each of the two remaining lesions identified for a second SIRT treatment. The lesion receiving an absorbed dose above the critical threshold can be seen to exhibit a complete response at the time of follow-up, whereas that receiving sub-threshold dosing exhibits stable disease
AOJNMB-5-66-g002.jpg
PMC5221688_01_AOJNMB-5-66-g002.jpg
F2
Dosimetry again was predictive of response, with lesions receiving 88 Gy and 8 Gy demonstrating a complete response and stable disease, respectively, at the time of follow-up in January 2015 (Figure 2).